Real-world apremilast experience in Australia

Introduction: This retrospective analysis undertaken in June 2017 was performed on 80 patients with chronic plaque psoriasis (CPP) who received apremilast in Australia and were enrolled in the Australasian Psoriasis Registry (APR). Apremilast received Therapeutic Goods Administration-approval in Australia in 2015. Other products approved for CPP include biologic agents targeting tumor necrosis factor alpha (TNF-α), interleukin (IL) 12/23 and IL-17, as well as conventional oral systemic therapies methotrexate, acitretin, and cyclosporine.